계정 가입
이미 존재한 계정
가입을 클릭하여 코인타임의 <a class="underline" href="#term-of-service">서비스 약관</a> 과 a class="underline" href="#privacy-policy">개인정보 보호 정책</a> . 에 동의함.
email 로 로그인
email 로 가입
사용자 이메일
수신함을 확인하세요
중의 링크를 통해 로그인 하세요
중의 링크를 통해 가입 하세요
Signia Therapeutics
company
About
Signia Therapeutics is an innovative French start-up company.
- 1 - 10
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- €1.30M
- Industries
- Medical
- Founded date
- Jan 1, 2017
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Signia Therapeutics proposes a breakthrough strategy to identify and repurpose rapidly, efficiently and at low cost already marketed drugs or to recycle unused drugs for new antiviral indication against several human respiratory viruses. These antiviral candidates could be directly evaluated in phase II clinical trials and/or quickly available in response to any widespread outbreak for which the medical community and patients have limited options.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
€1.30M
Signia Therapeutics has raised a total of
€1.30M
in funding over 2 rounds. Their latest funding was raised on
Oct 20, 2021 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 20, 2021 | Series A | €1.30M | 1 |
Neovacs
|
— | Detail |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
